An interesting analysis by the law firm Jones Day on the potential impact of the U.S. Dodd-Frank Act  over at Lexology. As the article puts it, you should first  review your OTC derivatives transactions and the identity and regulatory status of your counterparties to determine your exposure to various requirements. This won't be an easy task due to incomplete rules and the ambiguities arising under newly issued rules that have not been tested in the market. Whatever the size of your exposure to Dodd-Frank and global OTC regulations may be though, knowing your business first will help you plan on the appropriate next steps and avoid unnecessary delays. Maria L